Susquehanna International Group’s Baudax Bio, Inc. Common Stock BXRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q4 | – | Sell |
-10,699
| Closed | -$3.96K | – | 13782 |
|
|
2023
Q3 | $3.96K | Buy |
+10,699
| New | +$6.11K | ﹤0.01% | 11808 |
|
|
2023
Q2 | – | Sell |
-32,812
| Closed | -$55.8K | – | 13775 |
|
|
2023
Q1 | $55.8K | Buy |
+32,812
| New | +$83.5K | ﹤0.01% | 11651 |
|
|
2022
Q4 | – | Sell |
-1,213
| Closed | -$12K | – | 14680 |
|
|
2022
Q3 | $12K | Buy |
+1,213
| New | +$28.2K | ﹤0.01% | 12747 |
|
|
2022
Q1 | – | Sell |
-25
| Closed | -$4.62K | – | 14572 |
|
|
2021
Q4 | $8K | Buy |
+25
| New | +$15.7K | ﹤0.01% | 12964 |
|
|
2021
Q3 | – | Sell |
-25
| Closed | -$21.7K | – | 13975 |
|
|
2021
Q2 | $26K | Buy |
+25
| New | +$32.7K | ﹤0.01% | 12406 |
|
|
2021
Q1 | – | Sell |
-128
| Closed | -$256K | – | 13108 |
|
|
2020
Q4 | $181K | Buy |
128
+59
| +86% | +$121K | ﹤0.01% | 10119 |
|
|
2020
Q3 | $268K | Buy |
69
+20
| +41% | +$90.5K | ﹤0.01% | 8946 |
|
|
2020
Q2 | $283K | Buy |
+49
| New | +$235K | ﹤0.01% | 8459 |
|
Susquehanna International Group's BXRX Position: Q4 2023 in Review
Susquehanna International Group sold out of Baudax Bio, Inc. Common Stock (BXRX) in Q4 2023, closing a stake of 10,699 shares — an estimated $3.96K sold.
Susquehanna International Group first reported a position in BXRX in Q2 2020 and held it in 8 quarters. The position peaked at $283K in Q2 2020. 2 funds tracked by Wall St. Rank hold BXRX as of Q4 2023.
- Susquehanna International Group reported no remaining Baudax Bio, Inc. Common Stock position as of Q4 2023 after selling out during the quarter.
- Susquehanna International Group sold 10,699 Baudax Bio, Inc. Common Stock shares in Q4 2023, an estimated $3.96K.
- Susquehanna International Group first reported a position in Baudax Bio, Inc. Common Stock in Q2 2020 and held it in 8 quarters.
- Susquehanna International Group's Baudax Bio, Inc. Common Stock position peaked at $283K in Q2 2020.
- 2 funds tracked by Wall St. Rank held Baudax Bio, Inc. Common Stock as of Q4 2023.
Based on Susquehanna International Group's 13F filing for Q4 2023, filed 14 Feb 2024.